Glia: An important target for anti-inflammatory and antidepressant activity

Current Drug Targets

Volumn 14, Issue 11, 2013, Pages 1322-1328

  Hashioka, Sadayuki ^a   Miyaoka, Tsuyoshi ^a   Wake, Rei ^a   Furuya, Motohide ^a   Horiguchi, Jun ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Anti inflammatory effect; Antidepressants; Astrocyte; Cytokine; Depression; Microglia; Nitric oxide; Reactive oxygen species

Indexed keywords

CHEMOKINE; CLOMIPRAMINE; CXCL1 CHEMOKINE; CYTOKINE; DESIPRAMINE; FLUOXETINE; GAMMA INTERFERON; GLUTAMATE AMMONIA LIGASE; GLUTAMIC ACID; GLUTAMINE; IMIPRAMINE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MIRTAZAPINE; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROTROPHIN; PAROXETINE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; VENLAFAXINE;

ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DEGENERATIVE DISEASE; DEPRESSION; DISEASE ASSOCIATION; GLIA; HUMAN; IMMUNOREACTIVITY; MICROGLIA; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS; DEPRESSION; GLUTAMATE-AMMONIA LIGASE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; NERVE GROWTH FACTORS; NEURODEGENERATIVE DISEASES; NEUROGLIA;

EID: 84887968482     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/13894501113146660214     Document Type: Article

References (92)

1. Depression is a common illness and people suffering from depression need support and treatment: WHO marks 20th Anniversary of World Mental Health Day. Available at: http://www.who.int/mediacentre/news/notes/2012/mental_health_day_20121009/en/index.html [accessed February 22, 2013].
2. McNally L, Bhagwagar Z, Hannestad J. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr 2008; 13: 501-510.
3. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122: 509-522.
4. Slattery DA, Hudson AL, Nutt DJ. Invited review: the evolution of antidepressant mechanisms. Fundam Clin Pharmacol 2004; 18: 1-21.
5. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001; 62 Suppl 16: 10-17.
6. McGeer PL, McGeer EG. History of innate immunity in neurodegenerative disorders. Front Pharmacol 2011; 2: 77
7. Anisman H, Hayley S. Inflammatory factors contribute to depression and its comorbid conditions. Sci Signal 2012; 5: pe45
8. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-56.
9. Hashioka S, McGeer PL, Monji A, Kanba S. Anti-inflammatory effects of antidepressants: possibilities for preventives against Alzheimer's disease. Cent Nerv Syst Agents Med Chem 2009; 9: 12-19.
10. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 664-675.
11. Hashioka S. Antidepressants and Neuroinflammation: Can Antidepressants Calm Glial Rage Down? Mini-Reviews in Medicinal Chemistry 2011; 11: 555-564.
12. Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol 2002; 5: 401-412.
13. Dembo G, Park SB, Kharasch ED. Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology 2005; 102: 409-415.
14. Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006; 11: 680-684.
15. Arrigoni Martelli E, Tóth E, Segre AD, Corsico N. Mechanism of inhibition of experimental inflammation by antidepressant drugs. Eur J Pharmacol 1967; 2: 229-233.
16. Horrobin DF, Manku MS, Mtabaji JP. A new mechanism of tricyclic antidepressant action. Blockade of prostaglandin dependent calcium movements. Postgrad Med J 1977; 53 Suppl 4: 19-23.
17. Frommberger UH, Bauer J, Haselbauer P, Fraulin A, Riemann D, Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997; 247: 228-233
18. Sluzewska A, Rybakowski JK, Laciak M, Mackiewicz A, Sobieska M, Wiktorowicz K. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann N Y Acad Sci 1995; 762: 474-476.
19. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 2003; 170: 429-433.
20. Hashioka S, Klegeris A, Monji A, Kato T, Sawada M, McGeer PL, et al. Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp Neurol 2007; 206: 33-42.
21. Obuchowicz E, Kowalski J, Labuzek K, Krysiak R, Pendzich J, Herman ZS. Amitriptyline and nortriptyline inhibit interleukin-1 release by rat mixed glial and microglial cell cultures. Int J Neuropsychopharmacol 2006; 9: 27-35.
22. Ransohoff RM, Brown MA. Innate immunity in the central nervous system. J Clin Invest 2012; 122: 1164-71.
23. Graeber MB. Changing face of microglia. Science 2010; 330: 783-788.
24. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol 2010; 119: 7-35.
25. Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci 2009; 32: 638-647.
26. Hashioka S, Han YH, Fujii S, et al. Phosphatidylserine and phosphatidylcholine-containing liposomes inhibit amyloid beta and interferon-gamma-induced microglial activation. Free Radic Biol Med 2007; 42: 945-954.
27. Hashioka S, Klegeris A, Schwab C, McGeer PL. Interferon gamma-dependent cytotoxic activation of human astrocytes and astrocytoma cells. Neurobiol Aging 2009; 30: 1924-1935.
28. McGeer EG, McGeer PL. Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis 2010; 19: 355-361.
29. Maes M, Fisar Z, Medina M, Scapagnini G, Nowak G, Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012; 20: 127-150.
30. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006; 27: 24-31.
31. Bayer TA, Buslei R, Havas L, Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett 1999; 271: 126-128.
32. Steiner J, Bielau H, Brisch R, et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 2008; 42: 151-157.
33. Steiner J, Walter M, Gos T, et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation 2011; 8: 94.
34. Hashioka S, McLarnon JG, Ryu JK, et al. Pyrazole compound 2 MBAPA as a novel inhibitor of microglial activation and neurotoxicity in vitro and in vivo. J Alzheimers Dis 2011; 27: 531-541.
35. Klegeris A, Li J, Bammler TK, et al. Prolyl endopeptidase is revealed following SILAC analysis to be a novel mediator of human microglial and THP-1 cell neurotoxicity. Glia 2008; 56: 675-685.
36. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res 1996; 711: 163-174.
37. Castanon N, Médina C, Mormède C, Dantzer R. Chronic administration of tianeptine balances lipopolysaccharide-induced expression of cytokines in the spleen and hypothalamus of rats. Psychoneuroendocrinology 2004; 29: 778-790.
38. Chung ES, Chung YC, Bok E, et al. Fluoxetine prevents LPS induced degeneration of nigral dopaminergic neurons by inhibiting microglia-mediated oxidative stress. Brain Res 2010; 1363: 143-150
39. O'Sullivan JB, Ryan KM, Curtin NM, Harkin A, Connor TJ. Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration. Int J Neuropsychopharmacol 2009; 12: 687-699.
40. Chung YC, Kim SR, Jin BK. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. J Immunol 2010; 185: 1230-1237.
41. Chung YC, Kim SR, Park JY, et al. Fluoxetine prevents MPTP induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 2011; 60: 963-974.
42. Jin Y, Lim CM, Kim SW, et al. Fluoxetine attenuates kainic acid induced neuronal cell death in the mouse hippocampus. Brain Res 2009; 1281: 108-116.
43. Lim CM, Kim SW, Park JY, Kim C, Yoon SH, Lee JK. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res 2009; 87: 1037-1045.
44. Vollmar P, Nessler S, Kalluri SR, Hartung HP, Hemmer B. The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro inflammatory cytokines. Int J Neuropsychopharmacol 2009; 12: 525-536.
45. Zhu J, Wei X, Liu J, Hu Y, Xu J. Interaction of glia activation and neurotransmission in hippocampus of neuropathic rats treated with mirtazapine. Exp Clin Psychopharmacol 2009; 17: 198-203.
46. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000; 22: 370-379.
47. Tsao CW, Lin YS, Chen CC, Bai CH, Wu SR. Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 899-905.
48. Czeh B, Di Benedetto B. Antidepressants act directly on astrocytes: Evidences and functional consequences. Eur Neuropsychopharmacol 2012.
49. Manev R, Uz T, Manev H. Fluoxetine increases the content of neurotrophic protein S100beta in the rat hippocampus. Eur J Pharmacol 2001; 420: R1-R2.
50. Sillaber I, Panhuysen M, Henniger MS, Ohl F, Kuhne C, Putz B, et al. Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine. Psychopharmacology (Berl) 2008; 200: 557-572.
51. Ha E, Jung KH, Choe BK, et al. Fluoxetine increases the nitric oxide production via nuclear factor kappa B-mediated pathway in BV2 murine microglial cells. Neurosci Lett 2006; 397: 185-189.
52. Horikawa H, Kato TA, Mizoguchi Y, et al. Inhibitory effects of SSRIs on IFN-gamma induced microglial activation through the regulation of intracellular calcium. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1306-1316.
53. Hwang J, Zheng LT, Ock J, et al. Inhibition of glial inflammatory activation and neurotoxicity by tricyclic antidepressants. Neuropharmacology 2008; 55: 826-834.
54. Song JH, Marszalec W, Kai L, Yeh JZ, Narahashi T. Antidepressants inhibit proton currents and tumor necrosis factoralpha production in BV2 microglial cells. Brain Res 2012; 1435: 15-23.
55. Zhang F, Zhou H, Wilson BC, Shi J-S, Hong J-S, Gao H-M. Fluoxetine protects neurons against microglial activation-mediated neurotoxicity. Parkinsonism Relat Disord 2012; 18: S213-S217.
56. Liu D, Wang Z, Liu S, Wang F, Zhao S, Hao A. Anti-inflammatory effects of fluoxetine in lipopolysaccharide(LPS)-stimulated microglial cells. Neuropharmacology 2011; 61: 592-599.
57. Tynan RJ, Weidenhofer J, Hinwood M, Cairns MJ, Day TA, Walker FR. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun 2012; 26: 469-479.
58. Malberg JE, Blendy JA. Antidepressant action: to the nucleus and beyond. Trends Pharmacol Sci 2005; 26: 631-638.
59. Chen J, Rasenick MM. Chronic treatment of C6 glioma cells with antidepressant drugs increases functional coupling between a G protein (Gs) and adenylyl cyclase. J Neurochem 1995; 64: 724-732
60. Zhang L, Rasenick MM. Chronic treatment with escitalopram but not R-citalopram translocates Galpha(s) from lipid raft domains and potentiates adenylyl cyclase: a 5-hydroxytryptamine transporter-independent action of this antidepressant compound. J Pharmacol Exp Ther 2010; 332: 977-984.
61. Delfino F, Walker WH. Hormonal regulation of the NF-kappaB signaling pathway. Mol Cell Endocrinol 1999; 157: 1-9.
62. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18: 6853-6866.
63. Basso AM, Bratcher NA, Harris RR, Jarvis MF, Decker MW, Rueter LE. Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders. Behav Brain Res 2009; 198: 83-90.
64. Janda E, Visalli V, Colica C, et al. The protective effect of tianeptine on Gp120-induced apoptosis in astroglial cells: role of GS and NOS, and NF-kappaB suppression. Br J Pharmacol 2011; 164: 1590-1599.
65. Lee YH, Kim SH, Kim Y, Lim Y, Ha K, Shin SY. Inhibitory effect of the antidepressant imipramine on NF-kappaB-dependent CXCL1 expression in TNFalpha-exposed astrocytes. Int Immunopharmacol 2012; 12: 547-555.
66. Hisaoka K, Nishida A, Koda T, et al. Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells. J Neurochem 2001; 79: 25-34.
67. Hisaoka K, Takebayashi M, Tsuchioka M, Maeda N, Nakata Y, Yamawaki S. Antidepressants increase glial cell line-derived neurotrophic factor production through monoamine-independent activation of protein tyrosine kinase and extracellular signalregulated kinase in glial cells. J Pharmacol Exp Ther 2007; 321: 148-157.
68. Allaman I, Fiumelli H, Magistretti PJ, Martin JL. Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes. Psychopharmacology (Berl) 2011; 216: 75-84.
69. Kittel-Schneider S, Kenis G, Schek J, et al. Expression of monoamine transporters, nitric oxide synthase 3, and neurotrophin genes in antidepressant-stimulated astrocytes. Front Psychiatry 2012; 3: 33.
70. Takano K, Yamasaki H, Kawabe K, Moriyama M, Nakamura Y. Imipramine Induces Brain-Derived Neurotrophic Factor mRNA Expression in Cultured Astrocytes. J Pharmacol Sci 2012.
71. Rocha SM, Cristovao AC, Campos FL, Fonseca CP, Baltazar G. Astrocyte-derived GDNF is a potent inhibitor of microglial activation. Neurobiol Dis 2012; 47: 407-415.
72. Makar TK, Bever CT, Singh IS, et al. Brain-derived neurotrophic factor gene delivery in an animal model of multiple sclerosis using bone marrow stem cells as a vehicle. J Neuroimmunol 2009; 210: 40-51.
73. Liu W, Tang Y, Feng J. Cross talk between activation of microglia and astrocytes in pathological conditions in the central nervous system. Life Sci 2011; 89: 141-146.
74. Zhang D, Hu X, Qian L, O'Callaghan JP, Hong JS. Astrogliosis in CNS pathologies: is there a role for microglia? Mol Neurobiol 2010; 41: 232-241.
75. Leonardo CC, Eakin AK, Ajmo JM, et al. Delayed administration of a matrix metalloproteinase inhibitor limits progressive brain injury after hypoxia-ischemia in the neonatal rat. J Neuroinflammation 2008; 5: 34.
76. Raghavendra V, Tanga F, DeLeo JA. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther 2003; 306: 624-630.
77. Gwak YS, Kang J, Unabia GC, Hulsebosch CE. Spatial and temporal activation of spinal glial cells: role of gliopathy in central neuropathic pain following spinal cord injury in rats. Exp Neurol 2012; 234: 362-372.
78. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007; 8: 57-69.
79. Campbell S, MacQueen G. An update on regional brain volume differences associated with mood disorders. Curr Opin Psychiatry 2006; 19: 25-33.
80. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996; 93: 3908-3913.
81. Sheline YI, Gado MH, Price JL. Amygdala core nuclei volumes are decreased in recurrent major depression. Neuroreport 1998; 9: 2023-2028.
82. Pace TW, Miller AH. Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann N Y Acad Sci 2009; 1179: 86-105.
83. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 2003; 160: 1554-1565.
84. Warner-Schmidt JL, Duman RS. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 2006; 16: 239-249.
85. Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci USA 2003; 100: 13632-13637.
86. Carnevale D, De Simone R, Minghetti L. Microglia-neuron interaction in inflammatory and degenerative diseases: role of cholinergic and noradrenergic systems. CNS Neurol Disord Drug Targets 2007; 6: 388-397.
87. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-457
88. Bilici M, Efe H, Koroglu MA, Uydu HA, Bekaroglu M, Deger O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 2001; 64: 43-51.
89. Forlenza MJ, Miller GE. Increased serum levels of 8-hydroxy-2'deoxyguanosine in clinical depression. Psychosom Med 2006; 68: 1-7.
90. Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003; 8: 365-370.
91. Chopra K, Kumar B, Kuhad A. Pathobiological targets of depression. Expert Opin Ther Targets 2011; 15: 379-400.
92. Heiberg IL, Wegener G, Rosenberg R. Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats. Behav Brain Res 2002; 134: 479-484.